The content is available as a PDF (501.3 KB).
editorial . 2020 Jul 31:ciaa1132. doi: 10.1093/cid/ciaa1132
The Multidimensional Challenge of Treating COVID-19: Remdesivir is a Foot in the Door
Rajesh T Gandhi
1,✉
Rajesh T Gandhi, M.D
1
Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Find articles by Rajesh T Gandhi
1
Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
✉
Corresponding Author: Rajesh T. Gandhi, MD., Massachusetts General Hospital, GRJ 504, 55 Fruit St, Boston, MA 02114, T: 617-724-9690; F: 617-726-7653; Email: rgandhi@mgh.harvard.edu
Received 2020 Jul 27.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC7454361 PMID: 32735655
See "Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care" in volume 73 on page e4166.
See commentary "Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care" in volume 73 on page e4166.